To characterize structural changes of HCQ retinopathy with SD-OCT after drug cessation. Setting: Private practice and academic institution. Patient Population: Patients at New England Eye Center and Ophthalmic Consultants of Boston in Boston, MA diagnosed with HCQ retinopathy and followed after drug cessation. Plaquenil dose based on weight Aralen phosphate Target of chloroquine When hydroxychloroquine treatment rheumatoid arthritis Bull's - eye maculopathy stages – Premaculopathy- normal Visual acuity VA. i. loss of foveal reflex ii. fine granular changes at the macula, seen better with red green filter iii. may be associated with small scotomas to a red target or amsler’s grid iv. reversible ; Early maculopathy – modest reduction VA 6/9-6/12 Plaquenil-induced maculopathy is a form of retinal toxicity that is associated with long-term use of of the anti-inflammatory medication plaquenil. The drug-induced maculopathy is associated with the following risk factors Cumulative dose level of 1,000 grams of plaquenil; Patients with existing retinal or macular disease; Patients over the. In the present day, the less toxic HCQ is used instead of chloroquine. The American Academy of Ophthalmology revised the screening guidelines in 2011 to include spectral domain-optical coherence tomography SD-OCT, fundus autofluorescence FAF, and multifocal ERG mfERG when available to assess the macula in patients taking HCQ. The new. Main Outcome Measures: SD-OCT findings suggestive of HCQ retinopathy before parafoveal ellipsoid disruption. Retrospective clinical data review by the Boston Image Reading Center. Plaquenil maculopathy oct of macula Retinal Physician - Hydroxychloroquine Maculopathy An., Plaquenil-Induced Toxic Maculopathy - Decision-Maker PLUS Can plaquenil cause a rashPlaquenil ulcerative colitisHydroxychloroquine medical definition Hydroxychloroquine, sold under the brand name Plaquenil Sanofi-Aventis, is an antimalarial drug that has gained widespread use in treating various autoimmune diseases, including systemic lupus erythematosus and rheumatoid arthritis. 1 By some estimates, more than 150,000 patients are on long-term therapy with this medication in America alone. 2 Retinal toxicity associated with HCQ use is. Multimodal Imaging in Plaquenil Toxicity. Expanded spectral domain-OCT findings in the early.. Early Plaquenil Toxicity Detected without Bull’s Eye Maculopathy. Abstract. Background The American Academy of Ophthalmology recommendations on screening for chloroquine CQ and hydroxychloroquine HCQ retinopathy are revised in light of new information about the prevalence of toxicity, risk factors, fundus distribution, and effectiveness of screening tools. Pattern of Retinopathy Although the locus of toxic damage is parafoveal in many eyes, Asian. Summary Macular degeneration is found among people who take Plaquenil, especially for people who are female, 60+ old, have been taking the drug for 1 - 2 years, also take medication Humira, and have Joint deposit. Chloroquine and hydroxychloroquine can cause toxic retinopathy due to their binding of melanin in the retinal pigmented epithelium RPE as well as direct toxicity to retinal ganglion cells. Early findings include mottling of the RPE and blunted foveal reflex. As the retinopathy progresses, a bull's-eye maculopathy develops, as seen in these photos.